Neuroendocrine Carcinomas Clinical Trials

15 clinical trials for Neuroendocrine Carcinomas across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — RECRUITING · PHASE1
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — RECRUITING · PHASE1
• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors — RECRUITING · PHASE1
• Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients — RECRUITING · PHASE2
• Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms — NOT_YET_RECRUITING · PHASE2
• A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers — SUSPENDED · PHASE2
• Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America — NOT_YET_RECRUITING
• Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma — NOT_YET_RECRUITING · PHASE2
• Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer — COMPLETED · PHASE2
• A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma — NOT_YET_RECRUITING · PHASE4
• A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours — OTHER · PHASE2
• Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin — OTHER · PHASE2
• Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas — COMPLETED · PHASE2
• Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients — COMPLETED · PHASE2
• Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors — OTHER · PHASE2

Refine this search